CytomX Therapeutics (CTMX) Equity Ratio (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed Equity Ratio for 12 consecutive years, with 0.68 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Ratio rose 502.14% year-over-year to 0.68, compared with a TTM value of 0.68 through Sep 2025, up 502.14%, and an annual FY2024 reading of 0.0, up 98.39% over the prior year.
- Equity Ratio was 0.68 for Q3 2025 at CytomX Therapeutics, down from 0.68 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.68 in Q2 2025 and bottomed at 0.41 in Q2 2023.
- Average Equity Ratio over 5 years is 0.04, with a median of 0.17 recorded in 2024.
- The sharpest move saw Equity Ratio plummeted 24204.87% in 2022, then soared 502.14% in 2025.
- Year by year, Equity Ratio stood at 0.0 in 2021, then tumbled by 24204.87% to 0.33 in 2022, then grew by 28.46% to 0.24 in 2023, then soared by 98.39% to 0.0 in 2024, then soared by 18036.85% to 0.68 in 2025.
- Business Quant data shows Equity Ratio for CTMX at 0.68 in Q3 2025, 0.68 in Q2 2025, and 0.25 in Q1 2025.